论文部分内容阅读
目的 :探讨前列腺素E1治疗外周动脉闭塞性疾病 (PAOD)的临床疗效和安全性。方法 :4 5例肢体动脉硬化性闭塞症患者给予前列腺素E1治疗 ,10 0 μg/d ,静脉给药 ,疗程 14d ,观察治疗前后患者症状、无痛性行走距离、踝臂压力比率、患肢胫后动脉平均血液流速的变化以及不良反应。结果 :82 .2 %患者自觉症状改善或明显改善 ;无痛性行走距离由 (2 31.8± 78.9)m延长至(32 7 2± 85.7)m ;踝臂压力比率由 0 .59± 0 .31增至 0 .87± 0 .4 1;患肢胫后动脉平均血流速也由(2 .3± 1.2 )cm/s上升至 (3.4± 1.3)cm/s。而不良反应则较轻。结论 :前列腺素E1对外周动脉闭塞性疾病有较好的疗效及较轻的不良反应。
Objective: To investigate the clinical efficacy and safety of prostaglandin E1 in the treatment of peripheral arterial occlusive disease (PAOD). Methods: Forty-five patients with arteriosclerosis obliterans were treated with prostaglandin E1 (100 μg / d) for 14 days. The symptoms, painless walking distance, ankle-brachial pressure ratio, The mean posterior tibial artery blood flow changes and adverse reactions. Results: 82.2% patients improved or significantly improved their symptoms; the painless walking distance was prolonged from (2 31.8 ± 78.9) m to (32 72 ± 85.7) m; the ratio of ankle brachial pressure increased from 0 .59 ± 0.31 To 0.87 ± 0.41; the average blood flow velocity of the posterior tibial artery also increased from (2.3 ± 1.2) cm / s to (3.4 ± 1.3) cm / s. The adverse reactions are lighter. Conclusion: Prostaglandin E1 has better curative effect and less adverse reactions on peripheral arterial occlusive disease.